)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vivos Therapeutics
Vivos Therapeutics (VVOS) investor relations material
Vivos Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary2 Nov, 2026
Executive summary
Annual meeting set for Dec. 2, 2026, at 10:00 a.m. MST; voting instructions must be received by Dec. 1, 2026.
Ballot covers seven director elections and Proposals 2–10, including executive pay, auditor ratification, capital issuances, a reverse split, equity-plan expansion, and conversion to Nevada.
Voting matters and shareholder proposals
Board recommends FOR advisory approval of named executive officer compensation and recommends future say-on-pay votes every 3 years.
Proposal 10 seeks authority to adjourn the meeting if needed to solicit votes for Proposals 5–9.
Shareholders may provide voting instructions online, by phone, mail, or in person; unmarked items on a signed, returned form follow board recommendations.
Board of directors and corporate governance
Board recommends FOR election of R. Kirk Huntsman, Ralph E. Green, Anja Krammer, Mark F. Lindsay, Leonard J. Sokolow, Matthew Thompson, and Gregg C. E. Johnson.
Proposal 9 seeks approval to convert from a Delaware to a Nevada corporation, including the conversion plan, Nevada articles, and bylaws.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vivos Therapeutics
- Ten proposals include a reverse split, large preferred-stock issuances and Nevada conversion.VVOS
Proxy filing - Ten proposals seek Nasdaq compliance, financing flexibility, more equity capacity, and Nevada conversion.VVOSProxy filing
- A 10-proposal agenda puts dilution, Nasdaq compliance and Nevada conversion before stockholders.VVOSProxy filing
- Q2 2026 revenue up 35% year-over-year, with improved gross margin but persistent net losses.VVOSQ2 2026
- Capital-light, high-margin sleep apnea treatment model set for national expansion and rapid growth.VVOSWTR Insights Conference: Powered by The Small Cap Showcase
- Revenue up 70% in Q1 2026, but losses widened and Nasdaq delisting risk remains.VVOSQ1 2026
- Registers 3.96M shares for resale from warrant exercises, supporting a provider-focused OSA strategy.VVOSRegistration filing
- Q3 revenue up 17%, gross margin at 60%, with FDA clearance and financing needs ahead.VVOSQ3 2024
- Revenue up 9%, operating loss down 35%, and FDA clearances and alliances drive 2025 growth.VVOSQ4 2024
Next Vivos Therapeutics earnings date
Q3 202618 Nov, 2026
Vivos Therapeutics
Next Vivos Therapeutics earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vivos Therapeutics Inc is a medical technology company focused on the development and commercialization of treatments for sleep-disordered breathing, including obstructive sleep apnea. The company offers oral appliance therapy supported by a network of dental and medical providers. Its approach emphasizes non-invasive, daytime treatments. Vivos Therapeutics Inc is headquartered in Littleton, Colorado, and its shares are listed on the NASDAQ.